Reference
1. Baena-Cagnani CE, Berger WE, DuBuske LM, et al. Comparative effects
of desloratadine versus montelukast on asthma symptoms and use of beta
2-agonists in patients with seasonal allergic rhinitis and asthma.International archives of allergy and immunology.2003;130(4):307-313.
2. Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial
of montelukast plus inhaled budesonide versus double dose inhaled
budesonide in adult patients with asthma. Thorax.2003;58(3):211-216.
3. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards
TB. Montelukast, a once-daily leukotriene receptor antagonist, in the
treatment of chronic asthma: a multicenter, randomized, double-blind
trial. Montelukast Clinical Research Study Group. Archives of
internal medicine. 1998;158(11):1213-1220.
4. Aagaard L, Hansen EH. Paediatric adverse drug reactions following use
of asthma medications in Europe from 2007 to 2011. Int J Clin
Pharm. 2014;36(6):1222-1229.
5. Aldea Perona A, Garcia-Saiz M, Sanz Alvarez E. Psychiatric Disorders
and Montelukast in Children: A Disproportionality Analysis of the
VigiBase((R)). Drug safety. 2016;39(1):69-78.
6. Bygdell M, Brunlof G, Wallerstedt SM, Kindblom JM. Psychiatric
adverse drug reactions reported during a 10-year period in the Swedish
pediatric population. Pharmacoepidemiology and drug safety.2012;21(1):79-86.
7. Callero-Viera A, Infante S, Fuentes-Aparicio V, Zapatero L,
Alonso-Lebrero E. Neuropsychiatric reactions to montelukast.Journal of investigational allergology & clinical immunology.2012;22(6):452-453.
8. Cereza G, Garcia Dolade N, Laporte JR. Nightmares induced by
montelukast in children and adults. The European respiratory
journal. 2012;40(6):1574-1575.
9. Ibarra-Barrueta O, Palacios-Zabalza I, Mora-Atorrasagasti O,
Mayo-Suarez J. Effect of concomitant use of montelukast and efavirenz on
neuropsychiatric adverse events. The Annals of pharmacotherapy.2014;48(1):145-148.
10. Kocyigit A, Gulcan Oksuz B, Yarar F, Uzun F, Igde M, Islek I.
Hallucination development with montelukast in a child with asthma: case
presentation. Iranian journal of allergy, asthma, and immunology.2013;12(4):397-399.
11. Lafay-Chebassier C, Chavant F, Favreliere S, Pizzoglio V,
Perault-Pochat MC. Drug-induced Depression: a Case/Non Case Study in the
French Pharmacovigilance Database. Therapie. 2015;70(5):425-432.
12. Mann PBLWGPSFSSRD. Pharmacosurveillance and safety of the
leukotriene receptor antagonist (LTRA), montelukast. Clin Exp
Allergy Rev. 2001:300-304.
13. Marchand MS, Jonville-Bera AP, Autret-Leca E. [Psychiatric
disorders associated with montelukast: data from the National
Pharmacovigilance Database]. Archives de pediatrie : organe
officiel de la Societe francaise de pediatrie. 2013;20(3):269-273.
14. Wallerstedt SM, Brunlof G, Sundstrom A, Eriksson AL. Montelukast and
psychiatric disorders in children. Pharmacoepidemiology and drug
safety. 2009;18(9):858-864.
15. US Food and Drug Administration:FDA requires Boxed Warning about
serious mental health side effects for asthma and allergy drug
montelukast (Singulair). https://wwwfdagov/drugs.2020;accessed 1 March 2020.
16. US Food and Drug Administration:Early Communication about an
ongoing safety review of montelukast (Singulair).http://wwwfdagov/Drugs 2008;accessed 1 March 2020.
17. US Food and Drug Administration:Updated information on leukotriene
inhibitors: montelukast (marketed as Singulair), Zafirlukast (marketed
as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR).http://wwwfdagov/Drugs 2009;accessed 1 March 2020.
18. Narang R, Narang S, Narang D, Udeani G. Contemporary use of
montelukast and its association with depression in asthma and allergic
rhinitis patients. Chest. 2014;146(4):13A.
19. Jadad AR. Randomised Controlled Trials. 1998;London: BMJ
Publishing Group.
20. Higgins J, Green S. Cochrane handbook for systematic reviews of
interventions,v.5.1. Cochrane Collaboration Web site. 2011.
21. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma
in 6- to 14-year-old children: a randomized, double-blind trial.
Pediatric Montelukast Study Group. Jama. 1998;279(15):1181-1186.
22. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a
leukotriene-receptor antagonist, for the treatment of mild asthma and
exercise-induced bronchoconstriction. The New England journal of
medicine. 1998;339(3):147-152.
23. Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent
leukotriene receptor antagonist, causes dose-related improvements in
chronic asthma. Montelukast Asthma Study Group. The European
respiratory journal. 1998;11(6):1232-1239.
24. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast,
inhaled beclomethasone, and placebo for chronic asthma. A randomized,
controlled trial. Montelukast/Beclomethasone Study Group. Annals
of internal medicine. 1999;130(6):487-495.
25. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and
loratadine as treatment for seasonal allergic rhinitis: a randomized,
placebo-controlled clinical trial. The Journal of allergy and
clinical immunology. 2000;105(5):917-922.
26. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Efficacy and
tolerability of montelukast alone or in combination with loratadine in
seasonal allergic rhinitis: a multicenter, randomized, double-blind,
placebo-controlled trial performed in the fall. Annals of allergy,
asthma & immunology : official publication of the American College of
Allergy, Asthma, & Immunology. 2002;88(6):592-600.
27. Baumgartner RA, Martinez G, Edelman JM, et al. Distribution of
therapeutic response in asthma control between oral montelukast and
inhaled beclomethasone. The European respiratory journal.2003;21(1):123-128.
28. Yildirim Z, Ozlu T, Bulbul Y, Bayram H. Addition of montelukast
versus double dose of inhaled budesonide in moderate persistent asthma.Respirology (Carlton, Vic). 2004;9(2):243-248.
29. Shah AR, Sharples LD, Solanki RN, Shah KV. Double-blind, randomised,
controlled trial assessing controller medications in asthma.Respiration; international review of thoracic diseases.2006;73(4):449-456.
30. Clinical trial of low-dose theophylline and montelukast in patients
with poorly controlled asthma. American journal of respiratory and
critical care medicine. 2007;175(3):235-242.
31. Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of
montelukast in placebo-controlled pediatric studies and their open-label
extensions. Pediatric pulmonology. 2009;44(6):568-579.
32. Prenner BM, Lu S, Danzig MR. Safety of fixed-dose
loratadine/montelukast in subjects with allergic rhinitis. Allergy
and asthma proceedings. 2010;31(6):493-498.
33. Bernstein JA. Allergic and mixed rhinitis: Epidemiology and natural
history. Allergy and asthma proceedings. 2010;31(5):365-369.
34. Martinez FD, Vercelli D. Asthma. Lancet (London, England).2013;382(9901):1360-1372.
35. Dockhorn RJ, Bergner A, Connell JT, et al. Safety and efficacy of
loratadine (Sch-29851): a new non-sedating antihistamine in seasonal
allergic rhinitis. Annals of allergy. 1987;58(6):407-411.
36. Timonen M, Jokelainen J, Silvennoinen-Kassinen S, et al. Association
between skin test diagnosed atopy and professionally diagnosed
depression: a Northern Finland 1966 Birth Cohort study. Biological
psychiatry. 2002;52(4):349-355.
37. Kovacs M, Stauder A, Szedmak S. Severity of allergic complaints: the
importance of depressed mood. Journal of psychosomatic research.2003;54(6):549-557.
38. Eyre H, Baune BT. Neuroplastic changes in depression: a role for the
immune system. Psychoneuroendocrinology. 2012;37(9):1397-1416.
39. Djuric VJ, Cox G, Overstreet DH, Smith L, Dragomir A, Steiner M.
Genetically transmitted cholinergic hyperresponsiveness predisposes to
experimental asthma. Brain, behavior, and immunity.1998;12(4):272-284.
40. Overstreet DH, Daws LC, Schiller GD, Orbach J, Janowsky DS.
Cholinergic/serotonergic interactions in hypothermia: implications for
rat models of depression. Pharmacology, biochemistry, and
behavior. 1998;59(4):777-785.